Prifemilast (HPP737) vs Roflumilast (Zoryve foam)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: PDE4 · full Psoriasis pipeline
Prifemilast (HPP737)
Developed by Newsoara Biopharma under a licence from vTv Therapeutics
NCT07712731 · Phase 3 · completed
The trial randomized 607 participants to HPP737 or active treatment with apremilast and used triple masking of participants, care providers, and investigators. Its primary endpoints were clinical psoriasis measures.
Reported efficacy
To evaluate proportion of subjects at Week 16 achieving at least a 75% reduction(improvement) from baseline in PASI (Psoriasis Area and Severity Index) score (PASI 75); (From enrollment to end of treatment at 16 weeks); To evaluate proportion of subjects at Week 16 achieving sPGA (Static Physician's Global Assessment) rating of "clear (score 0) or almost clear (score 1)" (From enrollment to end of treatment at 16 weeks): Co-primary endpoints at week 16, prifemilast 20 mg once daily vs apremilast 30 mg twice daily: PASI 75 64.6% vs 35.3% and sPGA 0/1 55.6% vs 31.3% (both P<0.0001) (2026-10-09). (met)
Result source: NCT07712731
Roflumilast (Zoryve foam)
Marketed by Arcutis Biotherapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Prifemilast (HPP737) | Roflumilast (Zoryve foam) |
|---|---|---|
| PASI 75 | —Not posted · NCT07712731 | 50.1% vs 16.8%+33.3 vs placeboNCT05028582 |
| PASI 90 | —Not posted · NCT07712731 | —Not reported |
| PASI 100 | —Not posted · NCT07712731 | —Not reported |
| sPGA 0/1 | —Not posted · NCT07712731 | —Not reported |
| DLQI, change | —Not posted · NCT07712731 | —Not reported |
PASI 75
- Prifemilast (HPP737)
- —Not posted · NCT07712731
- Roflumilast (Zoryve foam)
- 50.1% vs 16.8%+33.3 vs placeboNCT05028582
PASI 90
- Prifemilast (HPP737)
- —Not posted · NCT07712731
- Roflumilast (Zoryve foam)
- —Not reported
PASI 100
- Prifemilast (HPP737)
- —Not posted · NCT07712731
- Roflumilast (Zoryve foam)
- —Not reported
sPGA 0/1
- Prifemilast (HPP737)
- —Not posted · NCT07712731
- Roflumilast (Zoryve foam)
- —Not reported
DLQI, change
- Prifemilast (HPP737)
- —Not posted · NCT07712731
- Roflumilast (Zoryve foam)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Prifemilast (HPP737): 0 of 4 rows · Roflumilast (Zoryve foam): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Roflumilast (Zoryve foam) |
|---|---|
| Dropout rate | 11%0.3% foama NCT05028582 · Phase 3 show 1 more result11.5% NCT04128007 · Phase 2 |
| Discontinued due to AEs | 1.8%0.3% foama NCT05028582 · Phase 3 show 1 more result2.5% NCT04128007 · Phase 2 |
| Serious AEs | 0.7%0.3% foama NCT05028582 · Phase 3 show 1 more result0.5% NCT04128007 · Phase 2 |
| Most frequent reported AEs | — |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Roflumilast (Zoryve foam)
show 3 more results
show 1 more result
show 5 more results
show 2 more results
show 1 more result
+ 5 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Prifemilast (HPP737)'s landscape · Roflumilast (Zoryve foam)'s landscape